Analyst Research

Report Title Price
Provider : Stock Traders Daily
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : Wright Reports

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Navidea Biopharmaceuticals Inc announces positive lymphoseek injection results on injection timing and surgery across multiple solid tumor types

Tuesday, 10 Jun 2014 04:30pm EDT 

Navidea Biopharmaceuticals Inc:Announces results from combined analyses of Phase 3 clinical trials that evaluated Lymphoseek efficacy in lymphatic mapping for identifying pathology-positive lymph nodes across multiple solid tumor types: melanoma, breast cancer and head and neck squamous cell carcinoma.Results indicated that Lymphoseek sensitivity for sentinel lymph node mapping was consistent across the tumor type studies, regardless of whether surgery was conducted on the same day as, or on the day after injection of Lymphoseek.Results from the study comprise part of an sNDA filing for Lymphoseek which is under review by the U.S. Food and Drug Administration. 

Company Quote

0.061 +7.27%
10:24am EST